Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy cocktail targets tough blood cancers

NCT ID NCT01592370

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug nivolumab (Opdivo), alone or combined with other drugs, in 320 people with relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma. The main goal was to check safety and side effects, especially for the nivolumab plus daratumumab combination. Researchers also looked at how well the tumors responded. The trial has completed, and results help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nivolumab (Opdivo), alone or combined with ipilimumab, lirilumab, daratumumab, pomalidomide, or dexamethasone

What this could lead to

If successful, this could point toward new treatment options for patients with hard-to-treat blood cancers like lymphoma and multiple myeloma.

What could go wrong

This is an early-phase trial focused on safety, not a proven treatment. Results may not lead to a standard therapy, and side effects can be serious.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA MULTIPLE MYELOMA NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

  • Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Division Of Hematology & Oncology Ctr. For Health Sciences

    Los Angeles, California, 90095, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Huntsman Cancer Institute At The Univ. Of Utah

    Salt Lake City, Utah, 84112, United States

  • John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • Local Institution

    Yvoir, B-5530, Belgium

  • Local Institution

    Bologna, 40138, Italy

  • Local Institution

    Chorzów, 41-500, Poland

  • Local Institution - 0001

    New York, New York, 10065, United States

  • Local Institution - 0002

    Rochester, Minnesota, 55905, United States

  • Local Institution - 0003

    Baltimore, Maryland, 21231, United States

  • Local Institution - 0004

    Philadelphia, Pennsylvania, 19111, United States

  • Local Institution - 0005

    Salt Lake City, Utah, 84112, United States

  • Local Institution - 0006

    Portland, Oregon, 97239, United States

  • Local Institution - 0007

    Philadelphia, Pennsylvania, 19104, United States

  • Local Institution - 0009

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0011

    Ann Arbor, Michigan, 48109, United States

  • Local Institution - 0012

    Los Angeles, California, 90095, United States

  • Local Institution - 0014

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0015

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0017

    Aurora, Colorado, 80045, United States

  • Local Institution - 0018

    Westwood, Kansas, 66205, United States

  • Local Institution - 0019

    Indianapolis, Indiana, 46202, United States

  • Local Institution - 0023

    Orlando, Florida, 32804, United States

  • Local Institution - 0028

    Columbus, Ohio, 43210, United States

  • Local Institution - 0033

    Omaha, Nebraska, 68130, United States

  • Local Institution - 0035

    Clovis, California, 93611, United States

  • Local Institution - 0037

    Skokie, Illinois, 60077, United States

  • Local Institution - 0039

    Athens, 11528, Greece

  • Local Institution - 0040

    Poznan, 61-848, Poland

  • Local Institution - 0042

    Wroclaw, 50-367, Poland

  • Local Institution - 0043

    Poitiers, Vienne, 86021, France

  • Local Institution - 0044

    Nantes, 44000, France

  • Local Institution - 0045

    Ghent, 9000, Belgium

  • Local Institution - 0047

    Sint-Niklaas, 9100, Belgium

  • Local Institution - 0049

    Warsaw, 02-776, Poland

  • Local Institution - 013

    New Haven, Connecticut, 06520, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • OHSU Center for Hematologic Malignancies

    Portland, Oregon, 97239, United States

  • The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21231, United States

  • University Of Michigan Health System

    Ann Arbor, Michigan, 48109, United States